Jinggen Liu

Jinggen Liu


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 March 2009 in The FEBS Journal
Verified
Journal Article
Open access
PDF file
XLXin Lin
Xin Lin
YWYu‐Jun Wang
Yu‐Jun Wang
QLQing Li
Qing Li
YHYuan‐Yuan Hou
Yuan‐Yuan Hou
MHMin‐Hua Hong
Min‐Hua Hong
JLJinggen Liu
Jinggen Liu
Chronic high doses of morphine inhibit the growth of various human cancer cell lines. However, the mechanisms by which such high‐dose morphine inhibits cell proliferation and induces cell death are not fully understood. Here we show that c‐Jun N‐terminal kinase (JNK) plays a pivotal role in high‐dose morphine‐induced apoptosis of SH‐SY5Y cells in a mitochondria‐dependent manner. Activation of JNK by morphine led to reactive oxygen species (ROS) generation via the mitochondrial permeability transition pore, because the mPTP inhibitor cyclosporin A significantly inhibited ROS generation. ROS in turn exerted feedback regulation on JNK activation, as shown by the observations that cyclosporin A and the antioxidant N‐acetylcysteine significantly inhibited the phosphorylation of JNK induced by morphine. ROS‐amplified JNK induced cytochrome c release and caspase‐9/3 activation through enhancement of expression of the proapoptotic protein Bim and reduction of expression of the antiapoptotic protein Bcl‐2. All of these effects of morphine could be suppressed by the JNK inhibitor SP600125 and N‐acetylcysteine. The key role of the JNK pathway in morphine‐induced apoptosis was further confirmed by the observation that decreased levels of JNK in cells transfected with specific small interfering RNA resulted in resistance to the proapoptotic effect of morphine. Thus, the present study clearly shows that morphine‐induced apoptosis in SH‐SY5Y cells involves JNK‐dependent activation of the mitochondrial death pathway, and that ROS signaling exerts positive feedback regulation of JNK activity.

6 April 2010 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
GLGang Lu
Gang Lu
QZQi-Xin Zhou
Qi-Xin Zhou
SKShuo Kang
Shuo Kang
QLQing-Lin Li
Qing-Lin Li
LZLiang-Cai Zhao
Liang-Cai Zhao
JLJinggen Liu
Jinggen Liu
Chronic exposure to opiates impairs hippocampal long-term potentiation (LTP) and spatial memory, but the underlying mechanisms remain to be elucidated. Given the well known effects of adenosine, an important neuromodulator, on hippocampal neuronal excitability and synaptic plasticity, we investigated the potential effect of changes in adenosine concentrations on chronic morphine treatment-induced impairment of hippocampal CA1 LTP and spatial memory. We found that chronic treatment in mice with either increasing doses (20–100 mg/kg) of morphine for 7 d or equal daily dose (20 mg/kg) of morphine for 12 d led to a significant increase of hippocampal extracellular adenosine concentrations. Importantly, we found that accumulated adenosine contributed to the inhibition of the hippocampal CA1 LTP and impairment of spatial memory retrieval measured in the Morris water maze. Adenosine A1receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine significantly reversed chronic morphine-induced impairment of hippocampal CA1 LTP and spatial memory. Likewise, adenosine deaminase, which converts adenosine into the inactive metabolite inosine, restored impaired hippocampal CA1 LTP. We further found that adenosine accumulation was attributable to the alteration of adenosine uptake but not adenosine metabolisms. Bidirectional nucleoside transporters (ENT2) appeared to play a key role in the reduction of adenosine uptake. Changes in PKC-α/β activity were correlated with the attenuation of the ENT2 function in the short-term (2 h) but not in the long-term (7 d) period after the termination of morphine treatment. This study reveals a potential mechanism by which chronic exposure to morphine leads to impairment of both hippocampal LTP and spatial memory.

23 August 2010 in Acta Pharmacologica Sinica
Verified
Journal Article
Closed access
YWYu-Hua Wang
Yu-Hua Wang
JSJian-Feng Sun
Jian-Feng Sun
YTYi-Min Tao
Yi-Min Tao
ZCZhi-Qiang Chi
Zhi-Qiang Chi
JLJinggen Liu
Jinggen Liu

3 October 2012 in Journal of Neuroscience
Verified
Journal Article
Open access
WWWei-Sheng Wang
Wei-Sheng Wang
SKShuo Kang
Shuo Kang
WLWen-Tao Liu
Wen-Tao Liu
MLMu Li
Mu Li
YLYao Liu
Yao Liu
JLJinggen Liu
Jinggen Liu
Recent evidence suggests that histone deacetylase (HDAC) inhibitors facilitate extinction of rewarding memory of drug taking. However, little is known about the role of chromatin modification in the extinction of aversive memory of drug withdrawal. In this study, we used conditioned place aversion (CPA), a highly sensitive model for measuring aversive memory of drug withdrawal, to investigate the role of epigenetic regulation of brain-derived neurotrophic factor (BDNF) gene expression in extinction of aversive memory. We found that CPA extinction training induced an increase in recruiting cAMP response element-binding protein (CREB) to and acetylation of histone H3 at the promoters of BDNF exon I transcript and increased BDNF mRNA and protein expression in the ventromedial prefrontal cortex (vmPFC) of acute morphine-dependent rats and that such epigenetic regulation of BDNF gene transcription could be facilitated or diminished by intra-vmPFC infusion of HDAC inhibitor trichostatin A or extracellular signal-regulated kinase (ERK) inhibitor U0126 (1,4-diamino-2,3-dicyano-1,4-bis(methylthio)butadiene) before extinction training. Correspondingly, disruption of the epigenetic regulation of BDNF gene transcription with U0126 or suppression of BDNF signaling with Trk receptor antagonist K252a or BDNF scavenger tyrosine kinase receptor B (TrkB)-Fc blocked extinction of CPA behavior. We also found that extinction training-induced activation of ERK and CREB and extinction of CPA behavior could be potentiated or suppressed by intra-vmPFC infusion ofd-cycloserine, a NMDA receptor partial agonist or aminophosphonopentanoic acid, a NMDA receptor antagonist. We conclude that extinction of aversive memory of morphine withdrawal requires epigenetic regulation of BDNF gene transcription in the vmPFC through activation of the ERK-CREB signaling pathway perhaps in a NMDA receptor-dependent manner.

21 November 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
JZJunli Zhao
Junli Zhao
JSJinyi Sun
Jinyi Sun
YZYang Zheng
Yang Zheng
YZYanrong Zheng
Yanrong Zheng
YSYuying Shao
Yuying Shao
Yi WangYi Wang
Yi Wang
Epileptic seizures are widely regarded to occur as a result of the excitation-inhibition imbalance from a neuro-centric view. Although astrocyte-neuron interactions are increasingly recognized in seizure, elementary questions about the causal role of astrocytes in seizure remain unanswered. Here we show that optogenetic activation of channelrhodopsin-2-expressing astrocytes effectively attenuates neocortical seizures in rodent models. This anti-seizure effect is independent from classical calcium signaling, and instead related to astrocytic Na+-K+-ATPase-mediated buffering K+, which activity-dependently inhibits firing in highly active pyramidal neurons during seizure. Compared with inhibition of pyramidal neurons, astrocyte stimulation exhibits anti-seizure effects with several advantages, including a wider therapeutic window, large-space efficacy, and minimal side effects. Finally, optogenetic-driven astrocytic Na+-K+-ATPase shows promising therapeutic effects in a chronic focal cortical dysplasia epilepsy model. Together, we uncover a promising anti-seizure strategy with optogenetic control of astrocytic Na+-K+-ATPase activity, providing alternative ideas and a potential target for the treatment of intractable epilepsy.

13 August 2007 in Biochemical Journal
Verified
Journal Article
Closed access
XLXin Lin
Xin Lin
QLQing Li
Qing Li
YWYu-Jun Wang
Yu-Jun Wang
YJYa-Wen Ju
Ya-Wen Ju
ZCZhi-Qiang Chi
Zhi-Qiang Chi
JLJinggen Liu
Jinggen Liu
Morphine is recommended as a first-line opioid analgesic in the pain management of cancer patients. Accumulating evidence shows that morphine has anti-apoptotic activity, but its impact on the therapeutic applications of antineoplastic drugs is not well known. The present study was undertaken to test the hypothesis that morphine might antagonize the pro-apoptotic activity of DOX (doxorubicin), a commonly used antitumour drug for the treatment of neuroblastoma, in cultured SH-SY5Y cells. In the present study we demonstrated that morphine suppressed DOX-induced inhibition of cell proliferation and programmed cell death in a concentration-dependent, and naloxone as well as pertussis toxin-irreversible, manner. Further studies showed that morphine inhibited ROS (reactive oxygen species) generation, and prevented DOX-mediated caspase-3 activation, cytochrome c release and changes of Bax and Bcl-2 protein expression. The antioxidant NAC (N-acetylcysteine) also showed the same effects as morphine on DOX-induced ROS generation, caspase-3 activation and cytochrome c release and changes in Bax (Bcl-2-associated X protein) and Bcl-2 protein expression. Additionally, morphine was found to suppress DOX-induced NF-κB (nuclear factor κB) transcriptional activation via a reduction of IκBα (inhibitor of nuclear factor κB) degradation. These present findings support the hypothesis that morphine can inhibit DOX-induced neuroblastoma cell apoptosis by the inhibition of ROS generation and mitochondrial cytochrome c release, as well as by blockade of NF-κB transcriptional activation, and suggests that morphine might have an impact on the antitumour efficiency of DOX.